Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DTYMK | P23919 | 1/20 | 0.38 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | FBP1 | P09467 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899549 | 1.00 | TSHR (0.48) | TSHRRXRATDP1L3MBTL1DTYMK | |
| SCHEMBL5231767 | 0.90 | TSHR (0.48) | TSHRRXRATDP1L3MBTL1DTYMK | |
| SCHEMBL6214961 | 0.79 | TSHR (0.57) | TSHRRXRATDP1L3MBTL1DTYMK | |
| SCHEMBL58249 | 0.78 | KMT2A (0.34) | TSHRTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28853079 | 0.78 | KMT2A (0.34) | TSHRTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28853081 | 0.78 | KMT2A (0.34) | TSHRTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL216109 | 0.75 | CYP1A2 (0.39) | TSHRTDP1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6304256 | 0.73 | TSHR (0.71) | TSHRTDP1L3MBTL1DTYMKSMN1; SMN2 | |
| SCHEMBL28842429 | 0.72 | TSHR (0.69) | TSHRTDP1L3MBTL1DTYMKSMN1; SMN2 | |
| SCHEMBL28194741 | 0.72 | TSHR (0.69) | TSHRTDP1L3MBTL1DTYMKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323990-B1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | DYNAMIT NOBEL AG (DE) | 2014-06-18 | — | — | EP | claimed |
| US-8558005-B2 | Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF-UND SYSTEMTECHNIK (DE) | 2013-10-15 | — | — | US | claimed |
| JP-2012500183-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110178308-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | claimed |
| EP-2323990-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 2011-05-25 | — | — | EP | claimed |
| WO-2010021409-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF - UND SYSTEMTECHNIK (DE) | 2010-02-25 | — | — | WO | claimed |
| EP-2323990-B1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | DYNAMIT NOBEL AG (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8558005-B2 | Methods for the production of 2-halo-4-nitroimidazole and intermediates thereof | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF-UND SYSTEMTECHNIK (DE) | 2013-10-15 | — | — | US | disclosed |
| US-20110178308-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| EP-2323990-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | Dynamit Nobel GmbH Explosivstoff- und Systemtechnik (DE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010143007-A1 | METHOD FOR THE PRODUCTION OF 2-HALOGENO-4-NITROIMIDAZOLE | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF-UND SYSTEMTECHNIK (DE) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010021409-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | DYNAMIT NOBEL GMBH EXPLOSIVSTOFF - UND SYSTEMTECHNIK (DE) | 2010-02-25 | — | — | WO | disclosed |
| CN-1391563-A | Therapeutic quinazoline derivatives | ASTRAZENECA AB (SE) | 2003-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178308-A1 | METHODS FOR THE PRODUCTION OF 2-HALO-4-NITROIMIDAZOLE AND INTERMEDIATES THEREOF | IL4I1, NUDT1, NISCH | TSHR 3843/4885RXRA 4373/4885TDP1 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.